Variant Pharmaceuticals Has a New Name - ZyVersa Therapeutics, Inc.
IC 100 is a monoclonal antibody that uniquely inhibits the adaptor ASC component of multiple inflammasomes, providing potential to treat a broad group of inflammatory disorders.
IC 100 inhibits ASC, blocking inflammasome formation, activation, and initiation of the inflammatory response.
IC 100 also inhibits the ASC component of ASC Specks, disrupting their structure and function, thereby preventing perpetuation of the massive inflammatory response.
By inhibiting both initiation and perpetuation of inflammation, IC 100 is expected to be effective for both stopping existing inflammation and preventing more inflammation from occurring in patients with inflammatory diseases.
Preclinical data summarized below demonstrate that IC 100 blocks the inflammatory cascade, as reflected by inhibition of both caspase-1 and IL-β.
Data below demonstrate IC 100 has lower immunogenicity (9%) than many biologics used to treat inflammatory diseases, suggesting IC 100 has less potential for acquired drug resistance.
IC 100 has strong pre-clinical data related to multiple indications, as summarized below.